Why the study?
Does antithymocyte globulin provide long-term benefit in multiple sclerosis patients?
Does antithymocyte globulin provide long-term benefit in multiple sclerosis patients?
Antithymocyte globulin does not provide long-term clinical benefit for multiple sclerosis patients at five years of follow-up.
No sustained benefit of antithymocyte globulin in MS at 5 years cautions against long-term use; leaves open biomarker-guided trials.
Multiple sclerosis patients treated with antithymocyte globulin (ATG) were re-evaluated after five years. No long term benefit was found. Notably, the group of patients with an elevated gamma globulin to total protein ration in their C.S.F. and who did particularly well after treatment with ATG also failed to show any long term benefit. Few long term detrimental effects of ATG immunosuppression were identified. The implications of the results are discussed as they relate to the use of immunosuppression in multiple sclerosis.
No takes yet. Share an insight, caveat, or question.
Kastrukoff et al. (1978) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: